sur Galenica AG (isin : CH0360674466)
Galenica Reports Robust Sales Growth in Third Quarter
Galenica AG has announced a continued increase in sales for the third quarter of 2024. The company achieved net sales of CHF 2,864.8 million, marking a growth of 4.1%, surpassing the overall pharmaceutical market in Switzerland which grew by 2.9%. The sales boost was attributed to a strong demand for generics and biosimilars, alongside an increase in cold-related healthcare needs.
The Products & Care segment saw a rise in net sales by 4.0% to CHF 1,242.6 million. Retail (B2C) sales experienced a modest growth of 3.8%, with local pharmacies contributing significantly. However, "Pharmacies at Home" registered a slight decline of 1.4%. In the Professionals (B2B) sector, sales grew by 5.8%, driven by strong performances in both Products & Brands and Services for Professionals.
The Logistics & IT segment reported an increase of 4.5% in net sales, with the Wholesale area and Logistics & IT Services both contributing positively to the overall performance.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galenica AG